Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor

  • US 10,828,259 B2
  • Filed: 04/10/2020
  • Issued: 11/10/2020
  • Est. Priority Date: 03/03/2015
  • Status: Active Grant
First Claim
Patent Images

1. A solid tablet formulation comprising ibrutinib and pharmaceutically acceptable excipients, wherein the ibrutinib is a compound with the structure of Compound 1,

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×